Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2015and issued 2016 product revenue guidance.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the U.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported the grant of an inducement award to its new Chief Executive Officer, Paris Panayiotopoulos.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its Board of Directors has unanimously approved the termination of the Company’s Section 382 Rights Agreement, or the …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its partner Otsuka Pharmaceutical Co.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will continue negotiations with the Economic Committee on Health Care Products in Franceregarding pricing and reimbursement for …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the initiation of a randomized Phase 3 trial of Iclusig® (ponatinib) in second-line patients with chronic myeloid leukemia (CML) …
Fitbit Inc (NYSE:FIT) shares fell over 7.48% in pre-market trading down to $37.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has achieved full enrollment in the pivotal Phase 2 ALTA trial of its investigational anaplastic lymphoma kinase …
